New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:14 EDTCPRXCatalyst Pharmaceutical announces dismissal of stockholder class action lawsuit
Catalyst Pharmaceutical announced that on January 3, the previously reported stockholder class action lawsuit that had been filed against Catalyst and certain of its officers and directors was dismissed without prejudice. In the Court's order, the plaintiffs were granted leave to file an amended complaint within 20 days. Catalyst has no information as to whether any such amended complaint is planned by the plaintiffs. If an amended complaint is filed in the case, Catalyst intends to vigorously defend the amended lawsuit.
News For CPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
16:56 EDTCPRXCatalyst director Charles O'Keeffe buys 5,000 shares of common stock
Subscribe for More Information
14:44 EDTCPRXCatalyst slips after competitor surprises with positive data, TheStreet says
Shares of Catalyst Pharmaceutical are falling after its privately held competitor, Jacobus Pharmaceuticals, surprised with the disclosure of positive clinical trial data showing "unequivocal evidence" that its experimental drug is an effective treatment for patients with Lambert-Eaton Myasthenic Syndrome, said TheStreet's Adam Feuerstein. Jacobus Pharma's drug, which can now reportedly be submitted to FDA for approval, has the same active ingredient as in Firdapse, the report added. Shares of Catalyst are down about 17% to $3.88 in afternoon trading. Reference Link
14:33 EDTCPRXCatalyst Pharmaceutical weakness a buying opportunity, says Piper Jaffray
Piper Jaffray expects Catalyst Pharmaceutical's Firdapse to gain approval first and secure Orphan designation for Lambert-Eaton myasthenic syndrome. The firm reiterates its Overweight rating and $7 price target and would be buyers on weakness.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use